High Mobility Group Box 1 ve Kanser

Mustafa Yıldırım; Dinç Süren; Özlem Demirpençe; Vildan Kaya

High Mobility Group Box 1 and Cancer

Yıl 2014, Sayı: 3, 182 - 186, 01.09.2014

Mustafa Yıldırım Dinç Süren Özlem Demirpençe Vildan Kaya

Öz

Aim: High mobility group box HMGB proteins are non-histone nuclear proteins which have many different functions. HMGB1 is the most important member of this family. It binds to the small groove of DNA nonspesifically and modifies the interaction of DNA with some of the transcription factors, including p53 and steroid hormone receptors. HMGB1 is secreted passively from necrotic cells and actively from inflammatory cells and binds to its most important receptor, RAGE receptor for advanced glycation end products . HMGB1 plays a role in cell differantiation, cell migration, tumor metastasis and inflammation. There is increasing evidence on the role of HMGB1 in progression of cancer, angiogenesis, invasion and metastasis. There are studies suggesting that HMGB1 may have an important role in cancer development. Thus, HMGB1 and its receptor RAGE have become important therapy targets. Therefore we think that studies that show the role of HMGB1 in prediction of therapy and determining the prognosis are important since they will help determine the types of cancer to be targeted

Anahtar Kelimeler

high mobility group box B1, cancer, apoptosis, angiogenesis, target therapies

Kaynakça

Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 2009;37:1107-14.
Stros M, Polanská E, Struncová S, Pospísilová S. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II alpha. Nucleic Acids Res 2009;37: 2070-86.
Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990;1049:231-43.
Alexandrova EA, Beltchev BG. Differences between HMG1 proteins isolated from normal and tumour cells. Biochim Biophys Acta 1987;915:399-405.
Alexandrova EA, Beltchev BG. Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun 1988;154:918-27.
Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 2009;89:948-59.
Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J. 2001;20:4337-40.
Thomas JO, Travers AA. HMG1 and 2, and related ‘architectural’ DNA binding proteins. Trends Biochem Sci 2001;26:167-74.
Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
Sharma A, Ray R, Rajeswari MR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 2008;26:843-51.
Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009;34:425-31.
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high- mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010;136:677-84.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101:9309-14.
Court EL, Smith MA, Avent ND, Hancock JT, Morgan LM, Gray AG, et al. DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. Leuk Res 2004;28:743-53.
Jantzen HM, Admon A, Bell SP, Tjian R. Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature 1990;344:830-6.
Topalova D, Ugrinova I, Pashev IG, Pasheva EA. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol 2008;40:1536-42.
Livesey KM, Tang D, Zeh HJ, Lotze MT. Not just nuclear proteins: ‘novel’ autophagy cancer treatment targets - p53 and HMGB1. Curr Opin Investig Drugs 2008;9:1259-63.
Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73- dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-64.
Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007;28:1957-67.
Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003;302:421-6.
El Marzouk S, Gahattamaneni R, Joshi SR, Scovell WM. The plasticity of estrogen receptor-DNA complexes: binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers. J Steroid Biochem Mol Biol 2008;110:186-195.
Shen X, Hong L, Sun H, Shi M, Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 2009;22:535-9.
Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin- associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 2009;8:864-72.
Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007;81:75-83.
Thorburn J, Frankel AE, Thorburn A. Regulation of HMGB1 release by autophagy. Autophagy 2009;5:247-9.
Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-42.
Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20:518-23.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59.
de Visser KE, Coussens LM. The inflammatory tumor
microenvironment and its impact on cancer development. Contrib Microbiol 2006;13:118-37.
Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:60-81.
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007;30:596-606.
Faham A, Bennett D, Altin JG. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 2009;27:5846-54.
Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751-60.
He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 2000;97:5768-72.
Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004;11:557-64.
Livesey KM, Kang R, Zeh HJ 3rd, Lotze MT, Tang D. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 2012;8:846-8.
Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H, et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013;59:762-8.
Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003;17:1295-7.
Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005;166:1259-63.
Sitohy B, Nagy J, Dvorak H. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L, et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 2013;5:884-8.
van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2012;32:363-74.
Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007;100:204-12.

High Mobility Group Box 1 ve Kanser

Yıl 2014, Sayı: 3, 182 - 186, 01.09.2014

Mustafa Yıldırım Dinç Süren Özlem Demirpençe Vildan Kaya

Öz

Amaç: High mobility group box HMGB proteinler hücrede çok farklı fonksiyonları olan non-histon nükleer proteinlerdir. HMGB1 bu ailenin en önemli üyesidir. DNA’nın küçük oluğuna nonspesifik şekilde bağlanarak p53, steroid hormon reseptörleri de dahil olmak üzere bazı transkripsiyon faktörlerinin DNA ile etkileşimini modifiye eder. HMGB1‘in nekrotik hücrelerden pasif, inflamatuar hücrelerden aktif olarak sekrete edilerek en önemli reseptörü olan RAGE receptor for advanced glycation end products ’e bağlanır. HMGB1 Hücre farklılaşması, hücre göçü, tümör metastazı ve inflamasyonda da rol oynamaktadır. Kanser progresyonunda, anjiogenezde, invazyon ve metastaz gelişiminde HMGB1 rolü ile ilgili kanıtlar giderek artmaktadır. Yapılan çalışmalar HMGB1‘in kanser gelişiminde önemli bir role sahip olabileceğini düşündürmektedir. Bu nedenle HMGB1 ve reseptörü RAGE önemli bir tedavi hedefi olmaya başlamıştır. Bu nedenle HMGB1’in tedaviyi predikte etme ve prognozu belirlemedeki rolünü aydınlatacak çalışmaların hangi kanserlerin hedeflenebileceğini göstermesi açısından önemli olduğunu düşünüyoruz

Anahtar Kelimeler

high mobility group box B1, kanser, apoptozis, anjiogenez, hedef tedaviler

Kaynakça

Zhang J, McCauley MJ, Maher LJ 3rd, Williams MC, Israeloff NE. Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic Acids Res 2009;37:1107-14.
Stros M, Polanská E, Struncová S, Pospísilová S. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II alpha. Nucleic Acids Res 2009;37: 2070-86.
Bustin M, Lehn DA, Landsman D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990;1049:231-43.
Alexandrova EA, Beltchev BG. Differences between HMG1 proteins isolated from normal and tumour cells. Biochim Biophys Acta 1987;915:399-405.
Alexandrova EA, Beltchev BG. Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem Biophys Res Commun 1988;154:918-27.
Kang HJ, Lee H, Choi HJ, Youn JH, Shin JS, Ahn YH, et al. Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers. Lab Invest 2009;89:948-59.
Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members’ review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. Embo J. 2001;20:4337-40.
Thomas JO, Travers AA. HMG1 and 2, and related ‘architectural’ DNA binding proteins. Trends Biochem Sci 2001;26:167-74.
Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5.
Sharma A, Ray R, Rajeswari MR. Overexpression of high mobility group (HMG) B1 and B2 proteins directly correlates with the progression of squamous cell carcinoma in skin. Cancer Invest 2008;26:843-51.
Gnanasekar M, Thirugnanam S, Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol 2009;34:425-31.
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high- mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol 2010;136:677-84.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101:9309-14.
Court EL, Smith MA, Avent ND, Hancock JT, Morgan LM, Gray AG, et al. DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines. Leuk Res 2004;28:743-53.
Jantzen HM, Admon A, Bell SP, Tjian R. Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins. Nature 1990;344:830-6.
Topalova D, Ugrinova I, Pashev IG, Pasheva EA. HMGB1 protein inhibits DNA replication in vitro: a role of the acetylation and the acidic tail. Int J Biochem Cell Biol 2008;40:1536-42.
Livesey KM, Tang D, Zeh HJ, Lotze MT. Not just nuclear proteins: ‘novel’ autophagy cancer treatment targets - p53 and HMGB1. Curr Opin Investig Drugs 2008;9:1259-63.
Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73- dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem 2002;277:7157-64.
Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin 2007;28:1957-67.
Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003;302:421-6.
El Marzouk S, Gahattamaneni R, Joshi SR, Scovell WM. The plasticity of estrogen receptor-DNA complexes: binding affinity and specificity of estrogen receptors to estrogen response element half-sites separated by variant spacers. J Steroid Biochem Mol Biol 2008;110:186-195.
Shen X, Hong L, Sun H, Shi M, Song Y. The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer. Oncol Rep 2009;22:535-9.
Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY. Chromatin- associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther 2009;8:864-72.
Ito N, DeMarco RA, Mailliard RB, Han J, Rabinowich H, Kalinski P, et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2007;81:75-83.
Thorburn J, Frankel AE, Thorburn A. Regulation of HMGB1 release by autophagy. Autophagy 2009;5:247-9.
Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006;203:1637-42.
Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20:518-23.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59.
de Visser KE, Coussens LM. The inflammatory tumor
microenvironment and its impact on cancer development. Contrib Microbiol 2006;13:118-37.
Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:60-81.
Dong Xda E, Ito N, Lotze MT, Demarco RA, Popovic P, Shand SH, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007;30:596-606.
Faham A, Bennett D, Altin JG. Liposomal Ag engrafted with peptides of sequence derived from HMGB1 induce potent Ag-specific and anti-tumour immunity. Vaccine 2009;27:5846-54.
Kuniyasu H, Yano S, Sasaki T, Sasahira T, Sone S, Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005;166:751-60.
He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci U S A 2000;97:5768-72.
Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem Biol 2004;11:557-64.
Livesey KM, Kang R, Zeh HJ 3rd, Lotze MT, Tang D. Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 2012;8:846-8.
Yan HX, Wu HP, Zhang HL, Ashton C, Tong C, Wu H, et al. p53 promotes inflammation-associated hepatocarcinogenesis by inducing HMGB1 release. J Hepatol 2013;59:762-8.
Völp K, Brezniceanu ML, Bösser S, Brabletz T, Kirchner T, Göttel D, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
Brezniceanu ML, Völp K, Bösser S, Solbach C, Lichter P, Joos S, et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003;17:1295-7.
Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S, et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005;166:1259-63.
Sitohy B, Nagy J, Dvorak H. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012;72:1909-14.
Wang W, Jiang H, Zhu H, Zhang H, Gong J, Zhang L, et al. Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 2013;5:884-8.
van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2012;32:363-74.
Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 2007;100:204-12.

Toplam 47 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Bölüm	Collection
Yazarlar	Mustafa Yıldırım Dinç Süren Özlem Demirpençe Vildan Kaya
Yayımlanma Tarihi	1 Eylül 2014
Yayımlandığı Sayı	Yıl 2014Sayı: 3

Kaynak Göster

EndNote	Yıldırım M, Süren D, Demirpençe Ö, Kaya V (01 Eylül 2014) High Mobility Group Box 1 ve Kanser. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi 3 182–186.

Makale Dosyaları

Tam Metin

Dergi Ana Sayfası
Arşiv